Nalbuphine 10mg/mL Injection

Nalbuphine 10mg/mL Injection is an injectable opioid agonist-antagonist analgesic used for moderate to severe pain for nalbuphine treatment. It may also be used as part of anesthesia-related pain management by trained clinicians. Nalbuphine can relieve pain through kappa-opioid agonist activity and mu-opioid antagonist activity, but it is still an opioid and can cause sedation, respiratory depression, dependence, misuse, and withdrawal problems. Nalbuphine can precipitate withdrawal in people physically dependent on full opioid agonists such as morphine, oxycodone, heroin, fentanyl, or methadone. Combining it with alcohol, benzodiazepines, sleeping pills, muscle relaxants, antipsychotics, gabapentinoids, or other opioids increases sedation and breathing-risk concerns.
Nalbuphine 10mg/mL Injection is given by healthcare professionals by IV, IM, or subcutaneous route as prescribed. Do not self-inject. Monitoring should include pain relief, sedation, breathing, blood pressure, and withdrawal symptoms.
Nalbuphine acts as a kappa-opioid receptor agonist and mu-opioid receptor antagonist, producing analgesia while limiting some mu-opioid effects.
Possible effects include sleepiness, dizziness, nausea, vomiting, sweating, dry mouth, headache, constipation, and injection-site discomfort. Serious concerns include slow breathing, severe low blood pressure, profound sedation, withdrawal, seizures, allergic reaction, and misuse or dependence.
Review opioid dependence, recent opioid use, respiratory disease, sleep apnea, head injury, low blood pressure, liver/kidney disease, biliary disease, pregnancy, breastfeeding, alcohol, benzodiazepines, sedatives, gabapentinoids, antidepressants, and MAOIs.
Moderate to severe pain or anesthesia-related analgesia when injectable nalbuphine is prescribed.
Provides supervised opioid analgesia for selected acute pain situations, with a mixed receptor profile that may be useful in specific clinical plans.
Nalbuphine 10mg/mL Injection is used for moderate to severe pain for injectable nalbuphine treatment.
Yes. Like other opioids, nalbuphine can slow breathing, especially with sedatives or respiratory disease.
Yes. Its antagonist activity can precipitate withdrawal in people dependent on full opioid agonists.
It has opioid misuse, dependence, and withdrawal risks, so use should be monitored.
Alcohol, benzodiazepines, sleeping pills, other opioids, muscle relaxants, and gabapentinoids increase sedation and breathing risk.
Nalbuphine, Opioid agonist antagonist, Moderate severe pain, Respiratory depression warning, Precipitated opioid withdrawal, Supervised analgesia, AR: Nalbuphine /mL حقن, FR: Nalbuphine /mL, PT: Nalbuphine /mL injeção, ES: Nalbuphine /mL inyección, RU: Nalbuphine /mL инъекция, ID: Nalbuphine /mL injeksi, VI: Nalbuphine /mL thuốc tiêm, MS: Nalbuphine /mL suntikan, TL: Nalbuphine /mL iniksyon, ZH-SG: Nalbuphine /mL 注射剂
International B2B Enquiry
Send a structured B2B enquiry for Nalbuphine 10mg/mL Injection under Pain Relief. Global Medicines Export helps international buyers review product information, pack details, quantity requirements, destination-market needs, quotation support and export documentation coordination from India.
Product name, required strength or pack, expected quantity, destination country, buyer type and preferred manufacturer if any.
Availability, quotation support, documentation expectations and shipment-ready order communication can be reviewed before confirmation.
Commercial invoice, packing information, manufacturer details, batch details and supporting documents where applicable and available.
Product availability, quotation, and documentation support are coordinated for international B2B enquiries.
Nalbuphine 10mg/mL Injection